Reprogramming Exosomes for Biomedical Applications
Project Number5R01EB031830-04
Contact PI/Project LeaderZHANG, YONG
Awardee OrganizationUNIVERSITY OF SOUTHERN CALIFORNIA
Description
Abstract Text
Abstract
Exosomes are extracellular vesicles secreted by many types of cells and play important roles in mediating
intercellular communications. Endogenous exosomes have been emerging as a new and attractive class of
therapeutics, owing to their unique and important characteristics. However, effective approaches remain limited
for targeting exosomes to desired cells and tissues. And few methods are available for active loading of protein
cargos into exosomes for cellular delivery. To address these challenges for broadening therapeutic utility of
exosomes and unleashing their full potential, we propose to develop an innovative platform technology, termed
synthetic multivalent antibodies retargeted exosomes (SMART-Exos). This will be achieved through genetically
and chemically engineering exosomes with functional antibodies, ligands, and enzymes, combined with
encapsulation of different types of therapeutic payloads. By integrating knowledge and technologies in exosome
biology, protein engineering, synthetic chemistry, and enzyme inhibitor design, we aim to design and generate
a series of SMART-Exos with new and/or enhanced functions and properties through distinct but complementary
strategies. The resulting SMART-Exos are expected to redirect exosomes toward target cells in high specificity
for modulating cellular functions and processes through receptor engagement and/or cargo delivery, leading to
the development of a general and versatile platform technology for next-generation investigational and
therapeutic exosomes.
Public Health Relevance Statement
Project Narrative
Exosomes are extracellular vesicles secreted by various types of cells and characterized by unique
properties for therapeutic development. Using a multidisciplinary strategy, this application is aimed to develop a
novel technology for genetically and chemically reprogramming native exosomes. This innovative class of
exosomes with new and/or improved functions and properties are expected to provide important research and
therapeutic tools for biomedical applications.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
072933393
UEI
G88KLJR3KYT5
Project Start Date
01-September-2021
Project End Date
31-May-2026
Budget Start Date
01-June-2024
Budget End Date
31-May-2026
Project Funding Information for 2024
Total Funding
$517,023
Direct Costs
$313,347
Indirect Costs
$203,676
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$517,023
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB031830-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB031830-04
Patents
No Patents information available for 5R01EB031830-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB031830-04
Clinical Studies
No Clinical Studies information available for 5R01EB031830-04
News and More
Related News Releases
No news release information available for 5R01EB031830-04
History
No Historical information available for 5R01EB031830-04
Similar Projects
No Similar Projects information available for 5R01EB031830-04